J.P. Maffrand

4.6k citations

56 papers · 3.8k · 1 hit paper · h-index 28

Impact in

Internal Medicine top 2%
Pharmacology top 0.5%
- Cannabis and Cannabinoid Research

Papers in

Molecular Biology 16
- Receptor Mechanisms and Signaling 8
Cardiology and Cardiovascular Medicine 16
- Antiplatelet Therapy and Cardiovascular Diseases 13

Co-authors: Jean‐Marc Herbert (9 shared papers)J. Gleye (2 shared papers)Jean‐Michel Augereau (2 shared papers)G. Le Fur (12 shared papers)Philippe Soubrié (3 shared papers)A. Bernat (14 shared papers)Florence Oury-Donat (1 shared paper)M. Bensaïd (1 shared paper)
Journals: Thrombosis Research (6 papers)Thrombosis and Haemostasis (6 papers)Journal of Pharmacology and Experimental Therapeutics (5 papers)Biochemical Pharmacology (3 papers)Molecular Pharmacology (2 papers)
Partner nations: France Italy United Kingdom

In The Last Decade

J.P. Maffrand

55 papers receiving 3.6k citations

J.P. Maffrand's Hit Papers

align trajectories log scale

Chelerythrine is a potent and specific inhibitor of protein kinase C 1990 · 1.1k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

1990 Biochemical and Biophysical Research Communications

Peers

Countries citing papers authored by J.P. Maffrand

Since Specialization

Citations

This map shows the geographic impact of J.P. Maffrand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.P. Maffrand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.P. Maffrand more than expected).

Fields of papers citing papers by J.P. Maffrand

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.P. Maffrand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.P. Maffrand. The network helps show where J.P. Maffrand may publish in the future.

Co-authors

The 25 scholars most cited alongside J.P. Maffrand, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J.P. Maffrand Line = papers co-authored together J.P. Maffrand links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 56 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Chelerythrine is a potent and specific inhibitor of protein kinase C Biochemical and Biophysical Research Communications ·Jean‐Marc Herbert, Jean‐Michel Augereau, J. Gleye, J.P. Maffrand Hit paper breakdown →	1990	1126
2	The Cannabinoid CB1 Receptor Antagonist SR141716 Increases Acrp30 mRNA Expression in Adipose Tissue of Obese fa/fa Rats and in Cultured Adipocyte Cells Molecular Pharmacology ·M. Bensaïd, Magali Gary‐Bobo, A. Esclangon, J.P. Maffrand, G. Le Fur, Florence Oury-Donat, Philippe Soubrié	2003	498
3	Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. Journal of Clinical Investigation ·C. Serradeil‐Le Gal, Jean Wagnon, Corinne Garcia, C Lacour, P. Guiraudou, B. Christophe, G. Villanova, Dino Nisato, J.P. Maffrand, G. Le Fur	1993	245
4	An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function. Journal of Clinical Investigation ·Paquita Nurden, Pierre Savi, E Heilmann, Claude Bihour, Jean Marc Herbert, J.P. Maffrand, Alan T. Nurden	1995	155
5	In vitro functional evidence of neuronal cannabinoid CB₁ receptors in human ileum British Journal of Pharmacology ·Tiziano Croci, L. Manara, Giulio Aureggi, Fabio Guagnini, Murielle Rinaldi‐Carmona, J.P. Maffrand, Gérard Le Fur, Sylvain Mukenge, Gianfranco Ferla	1998	133
6	Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats Kidney International ·Philip Janiak, Bruno Poirier, Jean‐Pierre Bidouard, C. Cadrouvele, Françoise Pierre, Laurent Gouraud, Isabelle Barbosa, Jürgen Dedio, J.P. Maffrand, G. Le Fur, Stephen O’Connor, Jean Marc Herbert	2007	108
7	Binding of [3H]-2-methylthio ADP to rat platelets--effect of clopidogrel and ticlopidine. Journal of Pharmacology and Experimental Therapeutics ·Pierre Savi, Marie-Claude Laplace, J.P. Maffrand, Jean‐Marc Herbert	1994	95
8	ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. Circulation Research ·S K Yao, J C Ober, J McNatt, Claude R. Benedict, Mark Rosolowsky, H. Vernon Anderson, Kai Cui, J.P. Maffrand, W B Campbell, L. Maximilian Buja	1992	87
9	Verbascoside Isolated from Lantana camara, an Inhibitor of Protein Kinase C Journal of Natural Products ·Jean Marc Herbert, J.P. Maffrand, K. Taoubi, Jean‐Michel Augereau, I. Fourasté, J. Gleye	1991	83
10	ADP Plays a Key Role in Thrombogenesis in Rats Thrombosis and Haemostasis ·J.P. Maffrand, A. Bernat, Denis Delebassée, G. Defreyn, Jean‐Pierre Cazenave, John L. Gordon	1988	76
11	Chapter 15 Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands Progress in brain research ·C. Serradeil-Le Gall, Jean Wagnon, G Valette, Gabriela Garcia, Marc Pascal, J.P. Maffrand, G. Le Fur	2002	76
12	Ticlopidine and Clopidogrel (SR 25990C) Selectively Neutralize ADP Inhibition of PGE1-Activated Platelet Adenylate Cyclase in Rats and Rabbits Thrombosis and Haemostasis ·G. Defreyn, Christian Gachet, Pierre Savi, F Driot, Jean‐Pierre Cazenave, J.P. Maffrand	1991	71
13	Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP Thrombosis Research ·Rosette Feliste, Denis Delebassée, Michel Simon, Hugues Chap, G. Defreyn, E. Vallée, Louis Douste‐Blazy, J.P. Maffrand	1987	65
14	Pharmacology of Ticlopidine: A Review Seminars in Thrombosis and Hemostasis ·Gheslain Defreyn, A. Bernat, Denis Delebassée, J.P. Maffrand	1989	61
15	The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1 Biochemical Pharmacology ·Christian Gachet, Jean‐Pierre Cazenave, Philippe Ohlmann, Cyrille Bouloux, Ghyslain Defreyn, Francis Driot, J.P. Maffrand	1990	51
16	Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells American Journal of Physiology-Heart and Circulatory Physiology ·C. Serradeil‐Le Gal, Jean‐Marc Herbert, Chantal Delisée, Paul Schaeffer, Danielle Raufaste, Corine Garcia, F. Dol, E. Marty, J.P. Maffrand, G. Le Fur	1995	48
17	[3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor. Molecular Pharmacology ·Catherine Labbé‐Jullié, J. Botto, Magdalena Mas, Joëlle Chabry, Jean Mazella, Jean‐Pierre Vincent, D. Gully, J.P. Maffrand, Patrick Kitabgi	1995	47
18	Platelet Inhibition Reduces Cyclic Flow Variations and Neointimal Proliferation in Normal and Hypercholesterolemic-Atherosclerotic Canine Coronary Arteries Circulation ·H. Vernon Anderson, J McNatt, Fred J. Clubb, Michael V. Herman, J.P. Maffrand, Fred DeClerck, Chul Ahn, L. Maximilian Buja, James T. Willerson	2001	45
19	Inhibition of vascular smooth muscle cell proliferation in culture by pentosan polysulphate and related compounds Thrombosis Research ·Raymond Paul, Jean Marc Herbert, J.P. Maffrand, J. Lansen, G. Modat, Jean‐Marie Pereillo, John L. Gordon	1987	43
20	Comparative Arterial Antithrombotic Activity of Clopidogrel and Acetyl Salicylic Acid in the Pig Thrombosis and Haemostasis ·Ch M Samama, Philippe Bonnin, M. Bonneau, G Pignaud, E. Mazoyer, O. Bailliart, J.P. Maffrand, P. Viars, Jacques Caen, L. O. Drouet	1992	41

About J.P. Maffrand

J.P. Maffrand is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine, Hematology, Cellular and Molecular Neuroscience and Surgery, having authored 56 papers that have together received 3.8k indexed citations. Recurring topics across this work include Antiplatelet Therapy and Cardiovascular Diseases (13 papers), Receptor Mechanisms and Signaling (8 papers), Neuropeptides and Animal Physiology (8 papers), Neuroendocrine regulation and behavior (6 papers), Venous Thromboembolism Diagnosis and Management (6 papers), Blood Coagulation and Thrombosis Mechanisms (6 papers), Platelet Disorders and Treatments (5 papers) and Electrolyte and hormonal disorders (5 papers). The work is most often cited by research in Internal Medicine (222 citations), Pharmacology (839 citations), Endocrine and Autonomic Systems (317 citations), Physiology (198 citations) and Cardiology and Cardiovascular Medicine (775 citations). J.P. Maffrand has collaborated with scholars based in France, Italy and United Kingdom. Frequent co-authors include Jean‐Marc Herbert, J. Gleye, Jean‐Michel Augereau, G. Le Fur, Philippe Soubrié, A. Bernat, Florence Oury-Donat, M. Bensaïd, Magali Gary‐Bobo and Pierre Savi. Their work appears in journals such as Thrombosis Research, Thrombosis and Haemostasis, Journal of Pharmacology and Experimental Therapeutics, Biochemical Pharmacology and Molecular Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

J.P. Maffrand

Impact in

Papers in i

In The Last Decade

J.P. Maffrand

J.P. Maffrand's Hit Papers

Peers

Countries citing papers authored by J.P. Maffrand

Fields of papers citing papers by J.P. Maffrand

All Works

About J.P. Maffrand

Explore authors with similar magnitude of impact

Papers in